Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. (Q51391762)

4 April 2018

title

Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. (English)

1 reference

4 April 2018

0 references

Marc De Hert

1

1 reference

4 April 2018

Aurélia Mittoux

series ordinal

2

1 reference

4 April 2018

Yuan He

series ordinal

3

1 reference

4 April 2018

Joseph Peuskens

series ordinal

4

1 reference

4 April 2018

publication date

5 September 2010

1 reference

4 April 2018

European Archives of Psychiatry and Clinical Neuroscience

published in

1 reference

4 April 2018

volume

261

1 reference

4 April 2018

issue

4

1 reference

4 April 2018

page(s)

231-239

1 reference

4 April 2018

https://scigraph.springernature.com/pub.10.1007/s00406-010-0142-x

exact match

0 references

cites work

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

The changing face of cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Schizophrenia and increased risks of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Physical illness and schizophrenia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Sertindole: efficacy and safety in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

The metabolic syndrome and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

A Systematic Review of Mortality in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Abnormal glucose metabolism in patients treated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Metabolic side effects of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Influence of antipsychotics on mortality in schizophrenia: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

Sertindole: safety and tolerability profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0142-X

The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year

21 January 2018

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Metabolic syndrome in people with schizophrenia: a review.

1 reference

12 December 2020

Metabolic syndrome and mental illness

1 reference

12 December 2020

The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists

1 reference

12 December 2020

Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review

1 reference

12 December 2020

The European sertindole safety and exposure survey: a follow-up study of 8600 patients

1 reference

12 December 2020

Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

1 reference

12 December 2020

Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

1 reference

12 December 2020

Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

1 reference

12 December 2020

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

12 December 2020

Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.

1 reference

12 December 2020

Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods.

1 reference

12 December 2020

10.1007/S00406-010-0142-X

Identifiers

DOI

1 reference

4 April 2018

release_ozrgxsi3cbfjjjlugg6pepupka

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ozrgxsi3cbfjjjlugg6pepupka

24 November 2022

mapped directly with Wikidata item

PubMed ID

20820795

1 reference

4 April 2018